Agentix is a clinical-stage pharmaceutical company developing treatments for metabolic diseases, specifically obesity, type 2 diabetes, and non-alcoholic fatty liver disease. Agentix focuses on peripherally-restricted cannabinoid type 1 (CB1) receptor antagonists designed to target metabolic functions in the liver and adipose tissue while staying outside the central nervous system. This approach aims to provide the metabolic benefits of CB1 inhibition without the psychiatric side effects seen in previous generations of those drugs. Agentix manages two pipeline assets: AGTX-2004, which is preparing for Phase 1 clinical trials, and AGTX-2003, which is in preclinical studies. Agentix operates as a virtual entity with no employees, using an Australian subsidiary to conduct development and access regional R&D tax incentives. The Agentix business model centers on advancing drug candidates through early-stage clinical development and then partnering with larger biopharmaceutical firms for late-stage trials and commercialization. Under this model, Agentix expects to generate income through milestone payments and royalties while remaining responsible for licensing fees and royalties to technology partners.